
The wild story of how a Cold War bioweapon became Botox — and how Allergan turned a sleepy ophthalmology drug into an enduring aesthetic franchise. Every part of this story looks nothing like your normal blockbuster...


science
Hosted by Alex Kesin and Matthew Pech · science · EN
Life sciences, under the hood. Deep dives into the patent filings, regulatory gauntlets, and capital-risks that shape the business of biology.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
23%
Guest openness
Selective
Sign up to generate a grounded pitch for Approved.
Signup to Generate a PitchLife sciences, under the hood. Deep dives into the patent filings, regulatory gauntlets, and capital-risks that shape the business of biology.
Approved is hosted by Alex Kesin and Matthew Pech. The show has published 6 episodes to date.
Recent episodes include "Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise" (18 September 2026, 217 minutes), "What is Approved?" (14 September 2026, 3 minutes), and "Blueprint Medicines: Chasing Gleevec to a $9B Allergy Drug" (4 August 2026, 150 minutes).
Approved publishes roughly monthly, with episodes averaging 124 minutes across 6 episodes.
Booking probability for Approved is 23%, and the host is rated Selective on guests. Approved requires a Pod Score of 80 or higher. Approved's contact route on record: verified email.
The strongest fits for Approved are Pharmaceuticals and Scientific Research & Development. Approved has a science audience.
Alex Kesin and Matthew Pech hosts Approved, a science podcast with 6 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

The wild story of how a Cold War bioweapon became Botox — and how Allergan turned a sleepy ophthalmology drug into an enduring aesthetic franchise. Every part of this story looks nothing like your normal blockbuster...

Approved
Approved tells the definitive stories behind the world's most interesting biotech ventures. Most people learn about the industry in a fragmented, ad hoc way-- an industry article here, a clinical trial readout there...

Blueprint Medicines was built to find the next Gleevec-style cancer drug. It ended up pivoting to allergic disease instead, and selling to Sanofi for $9B. This is the platform, the pivot, and who got paid. Blueprint...

Keytruda is Merck's $31 billion a year PD-1 inhibitor and the best-selling cancer drug of all time. In Episode 3 of Approved , Alex Kesin and Matthew Pech trace the development of pembrolizumab , featuring interviews...

Episode #2
Listen on Spotify Listen on Apple Podcasts Listen on YouTube TABLE OF CONTENTS (00:00:00) - Introduction (00:01:19) - Hayflick Limit (00:08:30) - Michael West & Founding of Geron (00:15:16) - Early Science & IP Strategy...

Episode #1
Listen on Spotify Listen on Apple Podcasts Listen on YouTube TABLE OF CONTENTS (00:00:00) - Introduction (00:04:40) - $50 of Dried Lizard Venom (00:29:17) - Fax of Death (00:43:04) - Sleeping Beauty Awakens (00:52:07)...
Recent guests on Approved. Study who booked and why before you pitch.
CEO, executive chairperson, philanthropist, Vesper Healthcare
professor in the UND School of Medicine & Health Sciences Department of Family & Community Medicine, Kings County Sheriff’s Department Air Support Unit
Professor of Medicine at Harvard Medical School, Brigham and Women's Hospital
Sweet Spot Medispo
PitchCentric classifies Approved under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ